Medgenics appoints Vice President of Clinical Affairs
Medgenics announced that it has appointed Dr. Ehud Shoshani, former CEO of Quintiles, Israel, as its Vice President of Clinical Affairs. Dr. Shoshani will manage the Company's Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy to treat anaemia, which is scheduled to start mid-2008 pending approval by the Israel Ministry of Health (MoH).
Dr. Shoshani's 13 years' experience in managing clinical trials includes his former position as Chief Executive Officer, Medical Director and Head of Clinical Operations of the Israel division of Quintiles. In addition, he has served as Medical Director at Omrix Biopharmaceutical, a blood products company (NASDAQ:OMRI), and at Gamida Cell, a stem cell therapy company.
Dr. Shoshani was awarded his MD in 1978 from the Technion Medical School in Haifa, Israel, and spent the next 16 years specializing in paediatrics, paediatric oncology and haematology before entering industry.
Organizations
Other news from the department price development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.